Introduction {#section1-0963689719825615}
============

Irreversible soft tissue loss caused by congenital defects, degeneration, trauma, or tumor resection is generally associated with physical, physiological, and psychological problems. Fat grafting is widely accepted as a preferred treatment for tissue volume reconstruction. However, the unpredictable absorption rates of adipose tissue, ranging from 20% to 90%, greatly influence the retention of fat grafts due to fat resorption, fibrosis, and calcification, which limits their therapeutic efficacy^[@bibr1-0963689719825615],[@bibr2-0963689719825615]^. To address this issue, a novel strategy called cell-assisted lipotransfer was developed, in which the fat tissue transplant is combined with a stromal vascular fraction containing abundant adipose-derived stromal cells (ASCs). In the early stage after autologous free fat transplantation, nutrient diffusion and neovascularization are urgently required for avascular fat graft survival. ASCs, which can differentiate into endothelial cells^[@bibr3-0963689719825615],[@bibr4-0963689719825615]^, promote the mobilization and recruitment of endothelial cells by secreting proangiogenic and antiapoptotic factors, such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), which play critical roles in accelerating angiogenesis^[@bibr5-0963689719825615][@bibr6-0963689719825615]--[@bibr7-0963689719825615]^. Furthermore, several cytokines secreted by ASCs participate in immune responses and the reconstruction and remodeling of graft tissue^[@bibr8-0963689719825615][@bibr9-0963689719825615]--[@bibr10-0963689719825615]^. In addition to retention of the fat graft, skin rejuvenation, and lesion healing are frequently observed around the recipient site, and are considered beneficial outcomes of the paracrine activity of ASCs. Several studies show that surviving fat grafts after cell-assisted lipotransfer consist of a mixture containing ASC-differentiated adipocytes and mature adipocytes^[@bibr11-0963689719825615]^, suggesting that adipogenic differentiation allows ASCs to serve as cellular resources for adipose tissue reconstruction, and that adipogenic differentiation-optimized methods could promote adipose implant enlargement^[@bibr12-0963689719825615],[@bibr13-0963689719825615]^. Although ASC-assisted transplantation shows promise for tissue regeneration, its efficacy varies due to the inconsistent function of ASCs.

Ginsenoside Rg1(G-Rg1), a steroidal saponin isolated from ginseng, protects against cerebral and myocardial infarction in animal models^[@bibr14-0963689719825615][@bibr15-0963689719825615][@bibr16-0963689719825615]--[@bibr17-0963689719825615]^. In addition, G-Rg1 promotes angiogenesis by inducing biological activity of human umbilical vein endothelial cells and endothelial progenitor cells^[@bibr18-0963689719825615][@bibr19-0963689719825615][@bibr20-0963689719825615]--[@bibr21-0963689719825615]^, promotes ASC growth and differentiation into a neural phenotype *in vitro* ^[@bibr22-0963689719825615],[@bibr23-0963689719825615]^, and increases microvessel density and adipogenesis in transplants *in vivo* by enhancing relative gene expression^[@bibr24-0963689719825615]^. For pharmacologic application, G-Rg1 could optimize the functional benefits of ASCs in combination with lipofilling in a dose-dependent manner. We previously found that the proliferation and neural differentiation of ASCs responds dose-dependently to G-Rg1 *in vitro*, consistent with research using mouse-derived ASCs^[@bibr22-0963689719825615],[@bibr23-0963689719825615]^. Moreover, we found that the chondrogenic differentiation of human breast ASCs (hbASCs) depended on G-Rg1 concentration^[@bibr25-0963689719825615]^. Thus, G-Rg1 may be a candidate adjuvant for ASC application in tissue remodeling, although how G-Rg1 influences the biological function of ASCs is not yet well understood. Therefore, we examined the effects of G-Rg1 on the paracrine activity and adipogenic differentiation capacity of hbASCs.

Materials and Methods {#section2-0963689719825615}
=====================

Patient Consent and Ethical Approval {#section3-0963689719825615}
------------------------------------

The present study was approved by the institutional ethical review board of Guangxi Medical University (Nanning, Guangxi, China). Written informed consent was provided by the donor patient.

Isolation and Identification of hbASCs {#section4-0963689719825615}
--------------------------------------

hbASCs were isolated and cultured as previously described^[@bibr24-0963689719825615],[@bibr25-0963689719825615]^ from spare breast adipose tissue from a 23-year-old healthy female patient without history of breastfeeding, who underwent breast reduction surgery, with body mass index (BMI) = 26.57 kg/m2 (height: 1.68 m, weight: 75 kg). P1 and P3 cells were analyzed using a Becton Dickinson FACSm Calibur flow cytometer. Cells (1 mL, 1 × 10^6^/mL) were incubated with fluorescein isothiocyanate (FITC)- or phycoerythrin (PE)-conjugated antibodies for 30 min. The following surface markers were used: CD29/PE, CD34/FITC, CD44/PE, CD45/FITC, CD49d/PE, CD73/PE, CD90/PE, CD105/PE, and CD133/FITC (BD Biosciences, Franklin Lakes, NJ, USA). Incubation with negative control IgG-PE antibodies was performed in the dark at room temperature for 30 min. Cell Quest Pro acquisition software (BD Biosciences) was used for data analysis. To assess cell differentiation, P3 hbASCs were cultured in adipogenic (DMEM, 10% FBS, 1% antibiotic/antimycotic, 200 μM indomethacin, 0.5 mM isobutyl-methylxanthine, 1 μM dexamethasone, 10 μM insulin), osteogenic (DMEM, 10% FBS, 1% antibiotic/antimycotic, 0.1 M dexamethasone, 50 μM ascorbate-2-phosphate, 10 mM b-glycerophosphate), or chondrogenic (DMEM, 1% FBS, 10 ng/ml TGF-β1, 1% antibiotic/antimycotic, 6.25 μg/ml insulin, 50 nM ascorbate-2-phosphate) culture media for 2--3 weeks, after which the relative staining method was performed.

For assessing adipogenic or osteogenic differentiation, differentiation medium were removed from the wells after 2--3 weeks induced culture, the cells were then rinsed with PBS, and fixed with 2 mL of 4% formaldehyde solution for 30 min; 1 ml oil red O working solution or 1 ml alizarin red S were added into one well to stain the cells for 3--5 min after being washed twice with PBS, and the cells then could be visualized and analyzed by microscope.

For assessing chondrogenic differentiation, the pellet was fixed with formalin, embedded with paraffin, sliced into 3--4 µm paraffin sections, and stained with the alcian blue solution for 30 min. The cells were washed in running tap water for 2 min, and visualized and analyzed by microscope.

Cell Proliferation {#section5-0963689719825615}
------------------

The proliferation of third-passage hbASCs was examined using the CCK-8 method. Cells were transferred to a 96-well plate at a density of 2 × 10^4^ cells/well and cultured for 24 h in an incubator at 37°C with 50 mL/L CO~2~, after which the normal nutrient solution was poured off. Cells were then randomly divided into five groups with six wells/group: basic media (BM) only without fetal bovine serum and antibiotics (control), BM + 0.1 μM G-Rg1, BM + 1 μM G-Rg1, BM + 10 μM G-Rg1, and BM + 100 μM G-Rg1. After an additional 10 days of culture, during which liquid supernatant was removed daily at the same time for each group, 50 μL CCK-8 working fluid was added to each well followed by 4 h of culture. After 10-min oscillations, optical density at 450 nm was detected using a microplate reader to generate proliferation curves.

Paracrine Activity {#section6-0963689719825615}
------------------

Five groups of hbASCs were cultured in 12-well plates at a density of 2 × 10^4^ cells/well with different concentrations of G-Rg1 (0--100 μM) in an incubator at 37°C with 50 mL/L CO~2~ for 14 days. After 7 and 14 days, supernatants were collected for analysis by enzyme-linked immunosorbent assay (ELISA). Levels of VEGF, FGF-2, epidermal growth factor (EGF), insulin-like growth factor (IGF)-1, stromal cell-derived factor (SDF)-1, platelet-derived growth factor (PDGF), angiopoietin (ANG), transforming growth factor-beta 1 (TGF-β1), tissue inhibitor of metalloproteinase (TIMP)-1, and interleukin (IL)-10 were measured using Quantikine colorimetric ELISA kits (R&D Systems, Minneapolis, MN, USA) according to the manufacturer's instructions.

Adipogenic Differentiation Capacity {#section7-0963689719825615}
-----------------------------------

hbASCs treated with different concentrations of G-Rg1 (0--100 μM) were cultured under an adipogenic induction condition for 2 weeks and then stained with Oil Red O. Adipocyte densities were measured in a double-blind manner in five visual fields under the same magnification. Cell numbers were normalized to square millimeters. Lipids were extracted from cells with 100% isopropanol and gentle shaking for 5 min. Lipid concentrations were measured based on absorbance at 510 nm in triplicate for each sample.

### Quantitative reverse transcription polymerase chain reaction {#section8-0963689719825615}

Total RNA was extracted using Trizol reagent (Invitrogen, Carlsbad, CA, USA) and treated with DNase I. cDNA conversion was performed using a RevertAid™ First Strand Synthesis Kit (Fermentas, Waltham, MA, USA). Quantitative reverse transcription polymerase chain reaction (qRT-PCR) was performed using SYBR® Green PCR Master Mixes on a StepOnePlus Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) with primer pairs for paracrine- and adipogenesis-related factors ([Table 1](#table1-0963689719825615){ref-type="table"}). Relative gene expression was analyzed using the 2^--ΔΔCt^ method and normalized to GAPDH expression. Data are presented as fold change relative to control.

###### 

qPCR Primer Sequences for Paracrine- and Adipogenesis-Related Target Genes.

![](10.1177_0963689719825615-table1)

  Gene       Forward                     Reverse
  ---------- --------------------------- --------------------------
  HIF-1α     GAAGAACTTTTAGGCCGCTCA       AGTCGTGCTGAATAATACCAC
  miRNA-31   AGGCAAGATGCTGGCATAGC        CAGTGCAGGGTCCGAGGTAT
  FIH-1      ATAGGCGGAGCTTCCGGTTC        GAATGGGCCTAGTCGGGAAG
  VEGF       CTTGCCTTGCTGCTCTACCTCC      CACACTCCAGGCCCTCGTCA
  FGF-2      GCGACCCTCACATCAAGCTAC       CCAGTTCGTTTCAGTGCCACA
  EGF        GACTGTGCTCCTGTGGGATG        GGTGGAGTAGAGTCAAGACAGTGA
  PDGF       CCACTAAGCATGTGCCCGAGA       TGGCACTTGACACTGCTCGT
  ANG        CCCTGCAAAGACATCAACACA       AGGTAAGCCATTTTCACAAGCA
  TGF-β1     TACCTGAACCCGTGTTGCTCT       CTGCCGCACAACTCCGGTGA
  IL-10      AGCTGTGGCCAGCTTGTTAT        TTCCATCTCCTGGGTTCAAG
  CXCR4      CAATGACTTGTGGGTGGTTG        GAAAGCCAGGATGAGGATG
  TIMP-1     CCTTATACCAGCGTTATGAGATCAA   AGTGATGTGCAAGAGTCCATCC
  PPARγ2     TGTCTCATAATGCCATCAGGT       TCTTTCCTGTCAAGATCGC
  FAD24      GGGAACTTGAGGAAGAGATCATTG    GGATCTGATAATATGGCAGATGCC
  C/EBPα     GCCGCGCACCCCGACCTCC         CCCCGCAGCGTGTCCAGTTCG
  ADD1       AGTACAAAGCCAAGTCCCGTTC      CCCGAATCACCGTCACTAGCAA
  GAPDH      CAAATTCCATGGCACCGTCA        GACTCCACGACGTACTCAGC

Statistical Analysis {#section9-0963689719825615}
--------------------

Data are shown as mean ± standard deviation (SD). Analysis of variance (ANOVA) was performed to test for differences among groups, thereby accounting for intra- and inter-group variation. Following significant ANOVAs, multiple pairwise comparisons were performed using paired *t*-tests. Statistical significance was set at two-tailed *P* \< 0.05. Data were analyzed using SPSS for Windows version 17.0 (Chicago, IL, USA).

Results {#section10-0963689719825615}
=======

Morphological Characterization and Multipotentiality of hbASCs {#section11-0963689719825615}
--------------------------------------------------------------

hbASCs began to adhere 6 h after seeding. Cells were initially small, round, and of non-uniform size with some mononuclear blood cells. They gradually stretched into short or long spindle shapes by 48 h, and showed typical fibroblast-like morphology after the third passage. Primary hbASCs reached 80--90% confluence after 7--8 days ([Fig. 1A](#fig1-0963689719825615){ref-type="fig"} I), whereas P1 hbASCs reached the same confluence in 3--4 days with a 1:3 split ratio ([Fig. 1A](#fig1-0963689719825615){ref-type="fig"} II-III). P3 hbASCs were cultured under adipogenic, osteogenic, and chondrogenic induction conditions, and lineage-specific morphologies of hbASCs were observed after 2 weeks, 3 weeks, and 2 weeks, respectively. Adipogenic, osteogenic, and chondrogenic differentiation were identified by positive Oil Red O ([Fig. 1A](#fig1-0963689719825615){ref-type="fig"} IV-V), Alizarin red ([Fig. 1A](#fig1-0963689719825615){ref-type="fig"} VI-VII), and Alcian blue ([Fig. 1A](#fig1-0963689719825615){ref-type="fig"} VIII-IX) staining, respectively, validating the multipotency of hbASCs.

![(A) Characterization of hbASCs. (I) Initial isolation and culture of primary hbASCs for 7--8 days. (II) P1 hbASCs cultured for 3--4 days with a 1:3 split ratio. (III) P3 hbASCs cultured for 3--4 days with a 1:3 split ratio. (IV) Adipogenic induction for 2 weeks. (V) Positive Oil Red O staining after adipogenic induction. (VI) Osteogenic induction for 3 weeks. (VII) Alizarin red staining after osteogenic induction. (VIII) Chondrogenic induction for 2 weeks. (IX) Alcian blue staining after chondrogenic induction. (B) Immunophenotypic characterization of hbASCs. The mesenchymal surface markers (I) CD29, (II) CD44. (V) CD49d, (VI) CD73, (VII) CD90, (VIII) CD105, and (IX) CD166, but not (II) CD34 or (IV) CD45 were expressed in all P1 hbASCs as determined by flow cytometry. (C) Immunofluorescence staining of P3 hbASCs demonstrated expression of CD29, CD44, CD49d, CD73, CD90, CD105, and CD133, but not CD34 or CD45 (*n* = 6).](10.1177_0963689719825615-fig1){#fig1-0963689719825615}

Immunophenotypic Characterization of hbASCs {#section12-0963689719825615}
-------------------------------------------

P1 hbASCs expressed the mesenchymal surface markers CD29 ([Fig. 1A](#fig1-0963689719825615){ref-type="fig"} I), CD44 ([Fig. 1A](#fig1-0963689719825615){ref-type="fig"} III), CD49d ([Fig. 1B](#fig1-0963689719825615){ref-type="fig"} V), CD73 ([Fig. 1B](#fig1-0963689719825615){ref-type="fig"} VI), CD90 ([Fig. 1B](#fig1-0963689719825615){ref-type="fig"} VII), CD105 ([Fig. 1B](#fig1-0963689719825615){ref-type="fig"} VIII), and CD166 (Fig. 21B IX), but not CD34 ([Fig. 1B](#fig1-0963689719825615){ref-type="fig"} II) or CD45 ([Fig. 1B](#fig1-0963689719825615){ref-type="fig"} IV) as determined by flow cytometry analysis ([Fig. 1C](#fig1-0963689719825615){ref-type="fig"}).

hbASC Proliferation {#section13-0963689719825615}
-------------------

hbASCs were cultured in BM containing 0, 0.1, 1, 10, or 100 μM G-Rg1, and CCK-8 tests were performed at 1--10 days. Compared with the control group (BM), cells in the 0.1 and 1 μM G-Rg1 groups had higher OD values, whereas cells in the 10 and 100 μM G-Rg1 groups had lower OD values at all time points after day 3 ([Fig. 2A](#fig2-0963689719825615){ref-type="fig"}). Cell proliferation reached a plateau on day 6 for all groups. These growth curves show that G-Rg1 affected hbASC proliferation in a dose-dependent manner, with cell proliferation declining in culture media containing ≥10 μM G-Rg1.

![(A) CCK-8 testing of hbASCs after 1--10 days of culture in BM only or BM containing 0, 0.1, 1, 10, or 100 μM G-Rg1. Data are presented as means. (B) Concentrations of VEGF, FGF-2, EGF, SDF-1, PDGF, ANG, TGF-β1, TIMP-1, and IL-10 in the supernatant of hbASCs cultured in BM only or BM containing 0.1, 1, 10, or 100 μM G-Rg1 after 7 and 14 days. (C) Relative mRNA expression of VEGF, FGF-2, EGF, PDGF, ANG, TGF-β1, HIF-1ɑ, miRNA31, FIH-1, TIMP-1, CXCR4, and IL-10 in hbASCs cultured in BM only or BM containing 0.1, 1, 10, or 100 μM G-Rg1 after 7 days. \**P* \< 0.05 vs. BM; ^\#^ *P* \< 0.05 vs. BM.](10.1177_0963689719825615-fig2){#fig2-0963689719825615}

Paracrine Activity of hbASCs {#section14-0963689719825615}
----------------------------

After culture for 7 and 14 days, concentrations of VEGF, FGF-2, EGF, SDF-1, PDGF, ANG, TGF-β1, TIMP-1, and IL-10 in the supernatant were measured by Quantikine colorimetric sandwich ELISA. Compared with the control group (BM), cytokine concentrations were higher in the 0.1 and 1 μM G-Rg1 groups and lower in the 10 and 100 μM G-Rg1 groups at both time points ([Fig. 2B](#fig2-0963689719825615){ref-type="fig"}), suggesting that G-Rg1 promotes the paracrine activity of hbASCs in dose-dependent manner within a low concentration range.

Paracrine- and Angiogenesis-Related Gene Expression in hbASCs {#section15-0963689719825615}
-------------------------------------------------------------

qRT-PCR on day 7 showed that gene expression of the paracrine-related factors VEGF, FGF-2, EGF, SDF-1, PDGF, ANG, TGF-β1, TIMP-1, and IL-10 was higher in the 0.1 and 1 μM G-Rg1 groups and lower in the 10 and 100 μM G-Rg1 groups compared with the control (BM) group ([Fig. 2C](#fig2-0963689719825615){ref-type="fig"}). Gene expression of the angiogenesis-related factors HIF-1α and CXCR4 as well as miRNA31 varied in a similar dose-dependent manner. By contrast, gene expression of FIH-1 was lower in the 0.1 and 1 μM G-Rg1 groups and higher in the 10 and 100 μM G-Rg1 groups.

Adipogenic Differentiation of hbASCs {#section16-0963689719825615}
------------------------------------

Oil Red O staining was used to assess adipogenic differentiation capacity 14 days after adipogenic induction. Compared with the control (BM) group, more stained cells were observed in the 0.1 and 1 μM G-Rg1 groups, and fewer stained cells were observed in the 10 and 100 μM G-Rg1 groups ([Fig. 3A](#fig3-0963689719825615){ref-type="fig"}). Quantification data showed a ∼50% increase in stained cells in the 0.1 and 1 μM G-Rg1 groups and a ∼50% decrease in stained cells in the 10 and 100 μM G-Rg1 groups ([Fig. 3B,C](#fig3-0963689719825615){ref-type="fig"}).

![(A) Adipocyte morphology and quantity were detected in five visual fields under the same magnification 14 days after adipogenic induction. Compared with the BM group (I--III), more oil red O-stained cells were observed in the 0.1 μM (IV--VI) and 1 μM (VII--IX) G-Rg1 groups, and fewer stained cells were observed in the 10 μM (X--XII) and 100 μM (XIII--XV) G-Rg1 groups (I, IV, VII, X, XII: ×100, II, V, VIII, XI, IV: ×200, III, VI, IX, XII, XV: ×400 magnification). (B), (C) Quantitative measurement of adipogenesis differentiation capacity. Compared with the BM group, adipocyte density (upper) and intracellular lipid content (lower) were increased in the 0.1 and 1 μM G-Rg1 groups and decreased in the 10 and 100 μM G-Rg1 groups (\**P* \< 0.05 vs. BM, \*\**P* \< 0.05 vs. BM). (D) Expression of PPARγ, FAD24, C/EBPα, and ADD1 in the BM only group and the 0.1, 1, 10, and 100 μM G-Rg1 groups (\**P* \< 0.05 .vs. BM, ^\#^ *P* \< 0.05 vs. BM).](10.1177_0963689719825615-fig3){#fig3-0963689719825615}

Adipogenic Marker Gene Expression in hbASCs {#section17-0963689719825615}
-------------------------------------------

At 14 days after adipogenic induction, gene expression of peroxisome proliferator-activated receptor-γ (PPARγ), factor for adipocyte differentiation 24 (FAD24), CCAAT/enhancer binding protein-α (C/EBPα), and adducin 1 (ADD1) was higher in the 0.1 and 1 μM G-Rg1 groups and lower in the 10 and 100 μM G-Rg1 groups compared with the control (BM) group ([Fig. 3D](#fig3-0963689719825615){ref-type="fig"}).

Discussion {#section18-0963689719825615}
==========

Although the efficacy of ASC-assisted lipofilling has been repeatedly confirmed in recent decades^[@bibr26-0963689719825615][@bibr27-0963689719825615]--[@bibr28-0963689719825615]^, controversies over the survival and regeneration mode of fat graft tissue still exist. Previous studies provide insight into the histological changes in fat transplants, revealing that transplanted adipose grafts can be divided into three regions: (1) an innermost area where both adipocytes and ASCs die; (2) a periphery zone where adipocytes and ASCs survive; and (3) an intermediate area where adipocytes die but ASCs survive and regenerate, which is considered to contribute to fat graft remodeling and retention^[@bibr11-0963689719825615]^. The proliferation and adipogenic differentiation of ASCs are commonly believed to play important roles in fat graft enlargement. Kølle et al. report that higher numbers of ASCs in a lipograft positively affects the final graft take, evidenced by a nearly 5-fold greater adipose tissue retention of ASC-enriched fat grafts compared with a control condition, as well as observations of more mature adipocytes and less necrotic fibrosis^[@bibr29-0963689719825615]^. Beside the ASCs, more and more scientists found there are other cells in fat tissue, called dedifferentiated fat (DFAT) cells, which are considered as the other "seed cell" resource for regenerative medicine since they possess multidirectional differentiation capacity similar to ASCs^[@bibr30-0963689719825615]^, suggesting differentiating into mature cell plays critical role in tissue regeneration. From this perspective, several techniques have been developed to optimize the efficacy of ASCs in fat transplantation, such as drug stimulation, physical treatment, or gene modification^[@bibr7-0963689719825615],[@bibr13-0963689719825615],[@bibr31-0963689719825615],[@bibr32-0963689719825615]^. By contrast, Yuan et al. report that most transplanted ASCs die during the 1st week after transplantation and suggest that angiogenic growth factors (e.g., VEGF, EGF) secreted by ASCs increase the neovascularization density of fat grafts^[@bibr33-0963689719825615]^. Besides the secretion of paracrine factors, our recent findings indicate that a portion of retained hbASCs in fat grafts differentiate into vascular endothelial cells, becoming an extra cell source for new vessel formation, and that CXCR4-modified ASCs enhance the neovascularization density of fat grafts^[@bibr34-0963689719825615]^. Neovascularization in the early stage after transplantation is critical to long-term fat retention and is associated with an increased number of inflammatory cells^[@bibr33-0963689719825615]^. This phenomenon suggests that immune activity contributes to angiogenesis, consistent with the theory of tumor angiogenesis, and that immunologic factors secreted by ASCs (e.g., TGF-β1^[@bibr35-0963689719825615]^, IL-10) are responsible for the enhanced density of neovascularization in fat grafts^[@bibr36-0963689719825615]^. We previously observed adipogenic differentiation and increased paracrine activity of ASCs in adipose grafts, suggesting both above-mentioned regeneration modes play important roles in ASC-assisted fat grafting, and that graft take is enhanced when ASCs are pretreated with certain drugs or genetic modifications^[@bibr22-0963689719825615],[@bibr33-0963689719825615]^. We suspect that the variable efficacy of ASCs in fat grafting results from different optimization methods between studies, which may induce different fat graft regeneration modes. Several modifications of the biological function of ASCs have been developed to improve the survival of fat grafts^[@bibr37-0963689719825615][@bibr38-0963689719825615]--[@bibr39-0963689719825615]^, some of which have been found efficacious in clinical practice^[@bibr40-0963689719825615]^, suggesting ASC optimization as a potential research direction in the field of regenerative medicine.

G-Rg1 is the active component in ginseng, which has repeatedly been shown to optimize the biological function of ASCs^[@bibr22-0963689719825615],[@bibr24-0963689719825615],[@bibr25-0963689719825615]^, but the mechanism of this effect has not been well understood. In the present study, we found that G-Rg1 improved the paracrine activity of ASCs in a dose-dependent manner. More specifically, the levels of paracrine factors including angiogenic factors (VEGF, FGF-2, EGF, PDGF, and ANG), immunologic factors (SDF-1, TGF-β1, and IL-10), and the matrix remodeling factor TIMP-1 were higher in all experimental groups compared with control group, while the paracrine factors' concentration increased more greater in media containing lower G-Rg1 concentrations (0--1 μM) than higher G-Rg1 concentrations (10--100 μM). Also, lower concentrations of G-Rg1 were associated with increased expression of genes associated with paracrine factors, angiogenesis, and adipogenic differentiation as well as increased proliferation and adipogenic differentiation capacity of hbASCs, whereas these biological functions of ASCs were inhibited by concentrations of G-Rg1 ≥ 10 μM. These results support our recent finding that the tissue regeneration capacity of ASCs is improved after treatment with 10 μg/mL G-Rg1^[@bibr39-0963689719825615]^, suggesting G-Rg1 as a candidate promoter of ASC-assisted fat engraftment through its effects on the growth, differentiation, and paracrine activity of ASCs.

To the best of our knowledge, the dose-response relationship between G-Rg1 and ASC-assisted fat graft retention *in vivo* has not yet been described in detail. Our results suggest that the regulatory effects of G-Rg1 on cell proliferation and adipogenic differentiation at lower concentrations are opposite to those at higher concentration. In the meantime, the results revealed that the paracrine activity of hbASCs was enhanced by G-Rg1 at all concentration levels, but more significantly in lower concentrations than at higher concentrations, while the gene expression of those paracrine factors as inhibited at concentrations of G-Rg1 ≥ 10 μM. So we considered that paracrine activation may be more sensitive to G-Rg1, although the specific mechanism remains to be explored in our future research. All in all, the study indicated that the concentration of G-Rg1 may influence the efficacy of hbASCs in adipose tissue regeneration. To optimize the application of G-Rg1 in ASC-assisted tissue reconstruction, the mechanisms underlying the effects of G-Rg1 on ASC adipogenic differentiation and paracrine activity must be addressed in future *in vivo* experiments.

In conclusion, our results indicate that G-Rg1 can positively influence the proliferation, paracrine activity, and adipogenic phenotype differentiation of hbASCs *in vitro*. More specifically, lower and higher concentrations of G-Rg1 may have opposing effects on the biological function of hbASCs, suggesting that the optimum concentration of G-Rg1 should be determined in future experiments.
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